SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
FAIL · Does not pass the screen
15.21 USD
At the last full screen 2026-08-27
Screened 2026-08-27 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
SELLAS Life Sciences Group, Inc. holds its Markup at $15.21. The statistical read favours the sellers, held for 10 days.
As held on the ledger · 2026-08-27
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 10 days
Price at the screen
$15.21
Valuation
N/A trailing · -152.10 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.49
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.28%
Below 33%
Interest-bearing debt is just 1.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
91.64%
Below 49%
Money owed to the company is 91.6% of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 2 covering, consensus Strong Buy. The average target sits +114% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Late stage cancer bet with no numbers to check
A biotech firm pushing one peptide drug through trials is like backing a single horse in a race where most never finish. SELLAS shows zero profit margin, negative 44 percent return on equity and a forward multiple that sits at negative 105 times, yet two analysts still call it a strong buy with a 28 dollar median target against the current 13 dollar price. Our own screen finds no usable financial ratios at all, which is why the opportunity rating stays at none.
The fair value calculation points to a 100 percent margin of safety, but that number rests on assumptions the company has not yet delivered in real cash flows or earnings. Without basic ratio data the ethical screen cannot even run, leaving the investment case resting on hope rather than evidence.
Risk sits in the usual late stage biotech traps: dilution, trial failure and cash burn that never turns into profit. The market can stay irrational longer than any single drug candidate can stay funded. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SLS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-13Markup$11.77+50.3%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 50.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 168% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 364%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (2 analysts) rates it none, with a mean price target of $10.
2026-07-18Markup$7.83+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 168% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 364%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (2 analysts) rates it none, with a mean price target of $10.
2026-07-03Markup$7.83+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$7.83Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.